RANTES Cancer Research Results

RANTES, CCL5: Click to Expand ⟱
Source:
Type:
RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), also known as CCL5
• RANTES/CCL5 is a chemokine that plays a central role in recruiting immune cells—such as T cells, eosinophils, and monocytes—to sites of inflammation.
• In the tumor microenvironment, RANTES can influence immune cell infiltration, which may either support anti-tumor responses or, conversely, facilitate a pro-tumorigenic inflammatory milieu depending on the context.
• RANTES is involved in modulating angiogenesis, cell migration, and the deposition of extracellular matrix components. These processes can affect tumor progression and metastasis.

-In several cancer types—including breast, lung, and colorectal cancers—elevated RANTES expression has been associated with more aggressive tumor behavior and, in some instances, poorer prognosis.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7137- GI,    6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-κB signaling
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - vitro+vivo, Pca, HMVP2
STAT3↓, TNF-α↓, NF-kB↓, cycD1/CCND1↓, survivin↓, cMyc↓, IL7↓, RANTES↓, BAX↑, Bcl-2↓, P21↑, p27/CDKN1B↑, SOCS1↑, IRF1↑, eff↑, TumVol↓, TumW↓, toxicity↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

IL7↓, 1,   IRF1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↑, 1,   Bcl-2↓, 1,   p27/CDKN1B↑, 1,   survivin↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

STAT3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,   RANTES↓, 1,   SOCS1↑, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RANTES, CCL5
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1221  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page